BREAKING: Futures Mixed After Jobs Data, Novo Nordisk (NVO) stock skidded early Wednesday after the Wegovy and Ozempic maker cut its sales outlook for the third time this year. The Danish drugmaker now expects sales to grow 8% to 11%, narrowed from its guidance three months ago for 8% to 14% growth, in constant currency. At the end of last year, Novo had expected 2025 sales to increase 16% to 24%. Novo's guidance cut follows a disappointing third-quarter showing. Sales came in at about $11.54 billion, base ...